CA Patent

CA3107169A1 — Pharmaceutical dosage form which can be administered orally and has modified release

Assigned to Bayer AG · Expires 2020-01-30 · 6y expired

What this patent protects

The invention relates to pharmaceutical dosage forms, which can be administered orally and have a modified release and contain sodium (3S)-3-(4-chloro-3-phenyl-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate, and to processes fo…

USPTO Abstract

The invention relates to pharmaceutical dosage forms, which can be administered orally and have a modified release and contain sodium (3S)-3-(4-chloro-3-phenyl-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate, and to processes for preparing the dosage forms and to the use thereof for treating and/or preventing diseases, in particular for treating and/or preventing cardiac, renal, pulmonary and ophthalmological disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA3107169A1
Jurisdiction
CA
Classification
—
Expires
2020-01-30
Drug substance claim
No
Drug product claim
No
Assignee
Bayer AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.